abbott.mediaroom.comGet Abbottmediaroomcom news - Abbott MediaRoom - Press

-- -- Investors OVERVIEW FINANCIALS STOCK INFO RESOURCES NEWS & EVENTS GOVERNANCE Newsroom NEWS PRESS RELEASES PRESS CONTACTS MEDIA LIBRARY HONORS EXPERTS EXECUTIVE TEAM Responsibility OVERVIEW Social Impact Sustainability Abbott Fund Live healthy Toggle navigation CONSUMERS HEALTHCARE PROFESSIONALS CAREERS Overview Working With Us Professionals Students Diversity & Inclusion Benefits Careers FAQS CONFERENCES & EVENTS Search Jobs ABOUT ABBOTT Overview Who We Are Our Heritage Abbott At A Glance Abbott FAQs Responsibility NEWS PRESS RELEASES PRESS CONTACTS MEDIA LIBRARY HONORS EXPERTS EXECUTIVE TEAM Press Releases For Professionals Product List -- accessibility accessibility Home Newsroom Press Releases -- PRESS RELEASES LEARN MORE -- WATCH NOW -- none accessibility -- Press Releases -- Business Citizenship Financial Innovation Product Recognition View All 2020 Archive 2019 Archive 2018 Archive Year All Years 2020 2019 2018 Category All Categories Business Citizenship Financial Innovation Product Recognition Uncategorized Keywords Go Advanced Search Search Search Headlines Only Category All Categories Business Citizenship Financial Innovation Product Recognition Uncategorized From To Asset Types Video Audio Photos Documents Events Standard Basic Search Apr 16, 2020 Photos 1 Abbott Reports First-Quarter 2020 Results - First-quarter sales growth of 2.5 percent; organic sales growth of 4.3 percent - Recently launched three breakthrough diagnostics tests for coronavirus (COVID-19) Apr 15, 2020 Photos 3 Abbott Launches Third COVID-19 Test, a Laboratory-Based Antibody Blood Test That Will Ship in the U.S. Starting Tomorrow - This adds to Abbott's previously announced COVID-19 molecular tests: the m2000™ lab-based test and ID NOW™ rapid point-of-care test - New antibody test will run on Abbott's ARCHITECT® i1000SR and i2000SR laboratory instruments and will expand to its new Alinity™ i system - Abbott begins shipping tomorrow and intends to distribute 4 million tests in April, ramping to 20 million in the U.S. per month in June and beyond Apr 14, 2020 Photos 1 Abbott Announces Virtual Attendance at Annual Meeting of Shareholders Apr 9, 2020 Photos 1 Abbott's TriClip™ Becomes First Device of its Kind to Receive CE Mark for Minimally Invasive Tricuspid Valve Repair - CE Mark for TriClip represents an important treatment option for people with severe tricuspid regurgitation, a difficult-to-manage heart condition - New system offers a proven safe and effective minimally invasive non-surgical solution - The TriClip System leverages Abbott's proven clip-based technology used in its MitraClip™ transcatheter mitral valve therapy Apr 8, 2020 Photos 1 Abbott's FreeStyle® Libre 14 Day System Now Available in U.S. for Hospitalized Patients with Diabetes During COVID-19 Pandemic -- More than 50% of people with diabetes who have been diagnosed with COVID-19 are hospitalized, according to a report from the Centers for Disease Control and Prevention (CDC)¹ -- FreeStyle Libre 14 day system can be used by frontline healthcare workers in hospitals to remotely monitor patients with diabetes who can scan² to minimize exposure to COVID-19 and preserve use of personal protective equipment (PPE) -- In partnership with the American Diabetes Association (ADA), Abbott will donate 25,000 FreeStyle Libre 14 day sensors to U.S. hospitals and medical centers in outbreak hotspots to help accelerate access to technology Mar 27, 2020 Photos 2 Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes - The Abbott ID NOW™ COVID-19 test brings rapid testing to the front lines - Test to run on Abbott's point-of-care ID NOW platform - a portable instrument that can be deployed where testing is needed most - ID NOW has the largest molecular point-of-care installed base in the U.S. and is available in a wide range of healthcare settings - Abbott will be making ID NOW COVID-19 tests available next week and expects to ramp up manufacturing to deliver 50,000 tests per day - This is the company's second test to receive Emergency Use Authorization by the FDA for COVID-19 detection; combined, Abbott expects to produce about 5 million tests per month Mar 19, 2020 Photos 1 Abbott Hosts Conference Call for First-Quarter Earnings Mar 18, 2020 Photos 2 Abbott Receives FDA Emergency Use Authorization and Launches Test to Detect Novel Coronavirus - The test will be used on the company's m2000 RealTime system that is currently available in hospitals and molecular laboratories in the U.S. - Abbott shipping 150,000 laboratory tests immediately; tests already sent to hospital and academic medical center labs in 18 states including Illinois, California, New York, Massachusetts and Washington - Company scaling up production at its U.S. manufacturing location to reach capacity for 1 million tests per week by end of March Mar 5, 2020 Photos 1 Abbott Aims to Optimize TAVI Implants with European Approval of FlexNav™ Delivery System for the Company's Portico™ Valve - New FlexNav™ delivery system improves control and delivery of the Portico™ TAVI valve even in complex clinical cases - The minimally invasive Portico procedure allows doctors to treat severe aortic valve stenosis without invasive surgery - Approval of the new delivery system follows first implants of the company's next-generation and investigational Navitor™ TAVI valve Feb 21, 2020 Photos 1 Abbott Declares 385th Consecutive Quarterly Dividend Feb 20, 2020 Photos 1 New Real-World Data Show that Abbott's FreeStyle Libre System Delivers Positive Health Outcomes for People with Type 1 and Type 2 Diabetes - Data at ATTD reinforce and add to a growing body of clinical research and real-world evidence from users of the FreeStyle Libre system around the world - People in Germany living with Type 1 or Type 2 diabetes on insulin showed a sustained reduction in HbA1c over one year following use of the FreeStyle Libre technology Feb 19, 2020 Photos 1 Abbott and Insulet Partner to Integrate Next-Generation Glucose Sensing and Automated Insulin Delivery Technologies for Seamless Diabetes Care - Collaboration will combine Abbott's leading continuous glucose monitoring (CGM) technology with Insulet's Omnipod Horizon™ Automated Insulin Delivery System to offer an accurate, easy-to-use, integrated digital health platform - Integrated technology will provide people living with diabetes around the world an affordable, transformational experience for improved glucose control Feb 18, 2020 Photos 1 Abbott Introduces Next-Generation Heart Rhythm Management Devices in Europe, Featuring State-of-the-Art Patient App and Bluetooth Connectivity - New Gallant™ high voltage devices offer patients and their doctors a smartphone app and Bluetooth connectivity designed to help doctors tailor therapy to a patient's unique clinical needs - Gallant ICD and CRT-D devices feature a more comfortable design, preferred by patients without compromising on battery longevity or high-voltage output, which remain among the highest in the industry Feb 4, 2020 Photos 1 Abbott's In-Development Fully Implantable Heart Pump System Earns FDA's Breakthrough Device Designation Feb 3, 2020 Photos 1 Abbott Announces First-of-Its-Kind Trial to Assess New Therapy Option for People at Risk of Stroke - The CATALYST trial will examine Abbott's Amplatzer™ Amulet™ device compared to non-vitamin K oral anticoagulants, the current standard in attempting to lower stroke and bleeding risks for patients with atrial fibrillation Jan 30, 2020 Photos 1 Abbott's Tendyne™ Device Receives World's First CE Mark for Transcatheter Mitral Valve Implantation - First-of-its-kind technology addresses critical need to eliminate mitral regurgitation when surgery or mitral repair is not an option - Tendyne valve provides relief from heart failure symptoms and quality-of-life improvement in high-surgical-risk patients - Together with MitraClip™, Tendyne expands Abbott's market-leading po...